AI assistant
Cyclerion Therapeutics, Inc. — Director's Dealing 2021
Mar 1, 2021
35315_dirs_2021-03-01_6034d71c-d86b-4ce3-9a4c-5997376095eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclerion Therapeutics, Inc. (CYCN)
CIK: 0001755237
Period of Report: 2021-02-25
Reporting Person: Wright Christopher I (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-25 | Common Stock | S | 2637 | $3.99 | Disposed | 42728 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.